Gain Therapeutics (GANX) 10-Q2024 Q3 Quarterly report

Filed: 14 Nov 24, 4:07pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accrual, add, age, Alder, Alzheimer, APIC, bid, cellular, chaperoning, Circuit, cognition, cognitive, consecutive, coordination, County, delist, delisting, departure, dropping, endoplasmic, evidenced, fibroblast, idiopathic, inactivation, Jeffrey, Lastly, letter, mentioned, mitochondrial, Montgomery, moved, neuromuscular, neuroprotective, Neuroscience, Notably, oxygen, PD, preemption, reactive, regained, rescue, reticulum, Riley, ROS, spread, stay, Tau, tenure, thinly, Trademark, vigorously, week, wild

Removed: ascending, bear, combat, dry, Gaucher, mouth, OfferingSM, PRSU

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

GANX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Gain Therapeutics, Inc. (the "Company") for the quarterly period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Gene Mack, as Interim Chief Executive Officer and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. §-1350, as adopted pursuant to §-906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2024

/s/

	By: /s/ Gene Mack
	Gene Mack
	Interim Chief Executive Officer and Chief Financial Officer
	(Principal Executive Officer and Principal Financial Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.